Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$8.11 -5.7%	$8.36	$6.10 ▼ $28.67	$561.65M	1.6	402,486 shs	378,694 shs
ENGN enGene	$2.88 -3.0%	$4.34	$2.63 ▼ $14.24	$146.81M	-0.36	128,447 shs	185,778 shs
KALV KalVista Pharmaceuticals	$11.64 -4.4%	$12.05	$7.30 ▼ $15.50	$578.69M	0.05	419,083 shs	466,826 shs
REPL Replimune Group	$7.41 -5.7%	$9.27	$4.92 ▼ $17.00	$570.68M	0.68	899,837 shs	663,362 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	+3.12%	-5.08%	+28.36%	-26.12%	-62.43%
ENGN enGene	+0.34%	-19.29%	-25.75%	-53.01%	-79.13%
KALV KalVista Pharmaceuticals	+2.35%	-7.02%	+6.01%	+31.39%	+0.83%
REPL Replimune Group	+1.95%	-21.48%	+6.94%	-38.83%	+22.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.877 of 5 stars	4.4	3.0	0.0	2.7	4.2	0.6
ENGN enGene	3.621 of 5 stars	4.5	3.0	0.0	2.8	2.5	0.6
KALV KalVista Pharmaceuticals	4.4575 of 5 stars	3.6	3.0	4.4	3.5	2.5	0.6
REPL Replimune Group	4.2843 of 5 stars	3.6	2.0	4.5	3.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	208.26% Upside
ENGN enGene	3.00	Buy	$23.29	708.53% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	113.34% Upside
REPL Replimune Group	3.13	Buy	$19.43	162.19% Upside

Current Analyst Ratings Breakdown

Latest ENGN, KALV, REPL, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00
5/2/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/1/2025	BCYC Bicycle Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $15.00
4/29/2025	ENGN enGene	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$18.00 ➝ $18.00
4/9/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/26/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/26/2025	KALV KalVista Pharmaceuticals	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$25.72M	21.84	N/A	N/A	$12.35 per share	0.66
ENGN enGene	N/A	N/A	N/A	N/A	$6.17 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$6.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$180.66M	-$3.14	N/A	N/A	N/A	-450.64%	-27.35%	-20.81%	N/A
ENGN enGene	-$55.14M	-$1.52	N/A	N/A	N/A	N/A	-16.69%	-14.27%	6/10/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-103.92%	-88.06%	7/10/2025 (Estimated)
REPL Replimune Group	-$215.79M	-$3.07	N/A	N/A	N/A	N/A	-54.84%	-42.97%	5/15/2025 (Estimated)

Latest ENGN, KALV, REPL, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q4 2025	REPL Replimune Group	-$0.75	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million
2/25/2025	Q4 2024	BCYC Bicycle Therapeutics	-$0.85	-$0.75	+$0.10	-$0.75	$5.47 million	$3.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
ENGN enGene	$1.58	54.90%	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	17.13	17.13
ENGN enGene	0.08	16.87	16.87
KALV KalVista Pharmaceuticals	N/A	6.87	6.87
REPL Replimune Group	0.14	11.43	11.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
ENGN enGene	64.16%
KALV KalVista Pharmaceuticals	N/A
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
ENGN enGene	13.70%
KALV KalVista Pharmaceuticals	10.50%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.18 million	Optionable
ENGN enGene	31	50.98 million	38.16 million	N/A
KALV KalVista Pharmaceuticals	100	49.72 million	44.23 million	Optionable
REPL Replimune Group	210	77.02 million	70.24 million	Optionable

ENGN, KALV, REPL, and BCYC Headlines

Recent News About These Companies

Jane Street Group LLC Has $3.83 Million Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

May 13 at 3:57 AM | marketbeat.com

Replimune Group (REPL) Projected to Post Quarterly Earnings on Thursday

May 13 at 2:21 AM | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Dimensional Fund Advisors LP

May 12 at 3:28 AM | marketbeat.com

Fcpm Iii Services B.V. Has $48.09 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

May 11 at 7:39 AM | marketbeat.com

Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $19.43

May 11 at 3:09 AM | americanbankingnews.com

172,202 Shares in Replimune Group, Inc. (NASDAQ:REPL) Bought by Crestline Management LP

May 10 at 6:05 AM | marketbeat.com

Replimune Group (REPL) Projected to Post Earnings on Thursday

May 10 at 1:53 AM | marketbeat.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025 | globenewswire.com

Braidwell LP Has $17.89 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

May 8, 2025 | marketbeat.com

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025 | globenewswire.com

Replimune Group, Inc. (NASDAQ:REPL) Stock Holdings Cut by Schonfeld Strategic Advisors LLC

May 8, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts

May 8, 2025 | marketbeat.com

Boxer Capital Management LLC Buys Shares of 1,796,341 Replimune Group, Inc. (NASDAQ:REPL)

May 4, 2025 | marketbeat.com

Invesco Ltd. Sells 92,952 Shares of Replimune Group, Inc. (NASDAQ:REPL)

May 4, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Wells Fargo & Company MN

May 2, 2025 | marketbeat.com

Price T Rowe Associates Inc. MD Purchases 1,083,633 Shares of Replimune Group, Inc. (NASDAQ:REPL)

April 29, 2025 | marketbeat.com

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

April 28, 2025 | seekingalpha.com

Renaissance Technologies LLC Buys 49,200 Shares of Replimune Group, Inc. (NASDAQ:REPL)

April 28, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Trading Down 2.9% - Should You Sell?

April 24, 2025 | marketbeat.com

Diadema Partners LP Purchases Shares of 114,000 Replimune Group, Inc. (NASDAQ:REPL)

April 24, 2025 | marketbeat.com

Marshall Wace LLP Takes $10.85 Million Position in Replimune Group, Inc. (NASDAQ:REPL)

April 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN, KALV, REPL, and BCYC Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$8.11 -0.49 (-5.70%)

As of 04:00 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

enGene NASDAQ:ENGN

$2.88 -0.09 (-3.03%)

As of 04:00 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

KalVista Pharmaceuticals NASDAQ:KALV

$11.64 -0.54 (-4.43%)

As of 04:00 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Replimune Group NASDAQ:REPL

$7.41 -0.45 (-5.73%)

As of 04:00 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time